Compare MREO & LOKV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MREO | LOKV |
|---|---|---|
| Founded | 2015 | 2024 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 294.7M |
| IPO Year | N/A | 2025 |
| Metric | MREO | LOKV |
|---|---|---|
| Price | $2.02 | $10.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.20 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 119.7K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $131.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.47 | $9.80 |
| 52 Week High | $3.88 | $11.67 |
| Indicator | MREO | LOKV |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | N/A |
| Support Level | $1.89 | N/A |
| Resistance Level | $2.37 | N/A |
| Average True Range (ATR) | 0.17 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 40.48 | 0.00 |
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Live Oak Acquisition Corp V is a blank check company.